San Francisco, CA – [Insert Date] – Crystalys Therapeutics, a clinical-stage biopharmaceutical company, has successfully closed a $130 million Series B financing round, a significant injection of capital poised to accelerate the clinical development and commercialization of its promising gout therapy, dotinurad. The funding round, spearheaded by Frazier Life Sciences and with substantial contribution from Novo Holdings, marks a pivotal moment for the company as it aims to establish dotinurad as a vital new treatment option for patients with gout, particularly those who do not respond adequately to existing standard-of-care therapies.
This substantial funding will be strategically deployed to advance dotinurad through mid-to-late-stage clinical trials, including crucial Phase III studies, and to lay the groundwork for its eventual market launch in key regions such as the United States, the United Kingdom, and Europe. Crystalys is focusing on addressing a significant unmet need within the gout treatment landscape, targeting a patient population often left with limited or no effective therapeutic alternatives.
The company’s CEO, James Mackay, emphasized the transformative potential of this funding, stating, "This Series B financing represents a significant validation of our scientific approach and the potential of dotinurad to reshape the treatment paradigm for gout. The capital secured will enable us to execute our ambitious development and commercialization strategies, bringing us closer to providing a much-needed therapeutic option for patients struggling with this debilitating condition."
Dotinurad: A Novel Approach to Gout Management
Gout, a painful form of inflammatory arthritis, is characterized by the accumulation of uric acid crystals in the joints and surrounding tissues. This buildup, known as hyperuricemia, is primarily driven by either overproduction or underexcretion of uric acid by the body. While current standard-of-care (SoC) treatments, such as xanthine oxidase inhibitors (XOIs) like allopurinol, aim to reduce uric acid production, a significant portion of patients either do not respond to these medications or experience intolerable side effects. Furthermore, a subset of patients requires more aggressive treatments, and for those who fail on existing therapies, options are severely limited.
Dotinurad distinguishes itself through its novel mechanism of action. As a selective urate transporter I (URAT1) inhibitor, dotinurad works by blocking the reabsorption of uric acid in the kidneys. This direct approach to increasing uric acid excretion represents a departure from the production-inhibiting strategy of many current treatments. Mackay elaborated on this key differentiator: "Our strategy with dotinurad is to tackle the root cause of gout by enhancing the body’s natural ability to eliminate excess uric acid. This mechanism has the potential to offer a more comprehensive and effective solution, particularly for patients who have not found relief with existing therapies."
Advancing Clinical Development: From Phase III to Long-Term Data
Crystalys is currently engaged in robust clinical development programs for dotinurad. The company is progressing with its Phase III trials, RUBY (NCT07089875) and TOPAZ (NCT07089888). These pivotal studies, funded by a substantial $205 million Series A raise in September 2025, are designed to definitively assess the efficacy and safety of dotinurad in a broad patient population.
A crucial component of the post-Phase III strategy, as outlined by Mackay, involves the initiation of open-label extension (OLE) studies for both RUBY and TOPAZ. These OLE studies are anticipated to run for approximately two years following the completion of the main Phase III trials. Their primary objective is to gather invaluable long-term safety data and to evaluate the durability of dotinurad’s therapeutic effect over an extended period. This comprehensive data set will be critical for regulatory submissions and for building confidence among healthcare providers regarding the sustained benefits of the drug.
Addressing Unmet Needs: The AMETHYST Study
Beyond its Phase III efforts aimed at a broader gout patient population, Crystalys is making a concerted effort to specifically target patients with significant unmet needs. The Phase II AMETHYST study (NCT07535034) is a cornerstone of this strategy. This trial is investigating dotinurad’s potential to benefit patients who are either ineligible for or intolerant to commonly prescribed XOIs, such as allopurinol. This patient group represents approximately 10-15% of the overall gout population, a substantial segment currently underserved by existing treatments.
Furthermore, AMETHYST will explore dotinurad’s efficacy and safety in patients who have proven unresponsive to Amgen’s Krystexxa (pegloticase). Krystexxa, a pegylated uricase enzyme, is considered a last-resort treatment for severe gout, and for patients who do not respond to it, there are currently no alternative therapeutic avenues. The inclusion of this patient cohort in the AMETHYST study highlights Crystalys’ commitment to developing dotinurad as a potential breakthrough therapy for the most challenging cases of gout. Mackay confirmed that the AMETHYST study is designed to enroll 90 patients, with topline results anticipated in the third quarter of 2027.
The rationale for focusing on these specific patient subgroups is underscored by stark statistics. It is estimated that approximately half of patients treated with standard-of-care therapies like allopurinol do not achieve an adequate response, leaving them susceptible to recurrent gout flares and progressive joint damage.
Dotinurad’s Global Journey and Market Potential
The journey of dotinurad is already marked by international progress. The drug has received regulatory approval and is marketed as Urece in several countries, including Japan, China, Thailand, the Philippines, and Taiwan. Crystalys secured the rights for dotinurad’s commercialization in the United States, the United Kingdom, and Europe from Fortress Biotech’s subsidiary, Urica Therapeutics, in 2024. This strategic acquisition positions Crystalys to leverage the existing global understanding of dotinurad and to build upon its established safety and efficacy profiles in new markets.
The gout market is substantial and projected to grow. In 2022, the gout market across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) was valued at an estimated $4.63 billion. GlobalData, the parent company of Clinical Trials Arena, forecasts that dotinurad, upon its potential approval in these key Western markets, could achieve $318 million in global sales by 2032. This projection underscores the significant commercial opportunity for a novel and effective gout therapy.
A Chronology of Dotinurad’s Development and Crystalys’ Growth
The recent Series B financing round is the latest milestone in a series of strategic advancements for Crystalys Therapeutics and the development of dotinurad:
- 2024: Crystalys Therapeutics secures the rights to commercialize dotinurad in the US, UK, and Europe from Fortress Biotech’s subsidiary, Urica Therapeutics. This strategic move lays the foundation for global market entry.
- September 2025: The company successfully raises $205 million in a Series A financing round. This substantial capital infusion is dedicated to funding the critical Phase III clinical trials for dotinurad, namely the RUBY and TOPAZ studies.
- [Current Date]: Crystalys Therapeutics announces the closure of a $130 million Series B financing round, led by Frazier Life Sciences and including significant participation from Novo Holdings. This funding is earmarked for advancing dotinurad’s clinical development, including long-term extension studies, and for preparing for its commercial launch in key Western markets.
- Q3 2027: Topline results from the Phase II AMETHYST study are anticipated. This trial is crucial for evaluating dotinurad’s efficacy and safety in patients intolerant to or ineligible for standard-of-care XOIs, as well as those unresponsive to Krystexxa.
- Post-Phase III Completion (estimated late 2027/early 2028): Open-label extension studies for the Phase III RUBY and TOPAZ trials are expected to commence, focusing on collecting long-term safety and durability data for dotinurad.
Supporting Data and Market Insights
The unmet need in gout management is a well-documented phenomenon. A significant percentage of patients inadequately controlled on current therapies underscores the demand for innovative solutions. The market for gout treatments is robust, indicating a strong commercial landscape for a drug that can effectively address the needs of a broader patient population.
- Patient Population: Approximately 10-15% of gout patients do not respond to or tolerate standard-of-care XOIs.
- SoC Inadequacy: Around half of patients treated with XOIs do not achieve adequate uric acid control.
- Limited Options for Refractory Patients: Patients who fail on Krystexxa have no available alternative treatments.
- Market Value: The global gout market was valued at $4.63 billion in 2022 across seven major markets.
- Sales Projection: GlobalData forecasts $318 million in global sales for dotinurad by 2032.
Implications for Patients and the Pharmaceutical Landscape
The successful Series B funding and the continued progress of dotinurad’s development carry significant implications:
- For Patients: The most immediate implication is the potential for a new, effective treatment option for individuals suffering from gout, especially those who have been left behind by current therapeutic standards. The focus on refractory and intolerant patient populations offers hope for improved quality of life, reduced disease burden, and a decrease in painful gout flares.
- For the Gout Treatment Paradigm: Dotinurad’s novel mechanism of action could fundamentally alter how gout is managed. If successful, it could usher in an era where both uric acid production inhibition and excretion enhancement are utilized in tandem or sequentially to optimize patient outcomes.
- For the Pharmaceutical Industry: The success of Crystalys Therapeutics highlights the ongoing innovation in the rare disease and unmet medical need space. It also underscores the value of targeting specific patient populations with differentiated therapeutic approaches. The investment from prominent venture capital firms like Frazier Life Sciences and Novo Holdings signals confidence in the biotechnology sector’s ability to deliver transformative therapies.
With this substantial financial backing, Crystalys Therapeutics is well-positioned to navigate the final stages of clinical development and to bring dotinurad to patients who desperately need it, potentially marking a new chapter in the fight against gout.
About the Author
